By doing this, vTv aims to rapidly receive topline data from the trial. The liver-selective glucokinase activator was found ...

Cadisegliatin is an oral, liver-selective glucokinase activator that has been generally well tolerated in over 500 subjects to date with up to six months of treatment. vTv Therapeutics expects to ...

The program includes the CATT1 Phase 3 trial in type 1 diabetes (T1D). Cadisegliatin is an oral, liver-selective glucokinase activator that has been generally well tolerated in over 500 subjects ...

Cadisegliatin is an oral, liver selective glucokinase activator that's being investigated as an adjunctive treatment to insulin for type 1 diabetes. The company announced the Phase 3 trial in July.